NCT04586504View on ClinicalTrials.gov

Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

May 14, 2024

Study Completion Date

May 14, 2024

Conditions
Procedural Anxiety
Interventions
DRUG

Intranasal midazolam

5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.

Trial Locations (1)

10032

NewYork Presbyterian Morgan Stanley Children's Hospital, New York

Sponsors
All Listed Sponsors
collaborator

Emergency Medicine Foundation

OTHER

collaborator

Mailman School of Public Health

UNKNOWN

lead

Columbia University

OTHER

NCT04586504 - Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children | Biotech Hunter | Biotech Hunter